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HYPERSENSITIVITY TO BACITRACIN
THE INFLUENCE OF DEGRADATION UPON ITS ECZEMATOGENIC EFFECT*
V. PIRILA, M.D.,t J. SAIJKKONEN, M.D. AND I. M. SANTAOJA
The common occurrence of simultaneous
cezematous hypersensitivity to bacitracin and
neomycin has been reported by Hjorth (1) and
by Pirild, and co-workers (2, 3, 4). The latter
found positive patch test reactions to bacitracin
in SO per cent of 228 cases of sensitivity to neo-
mycin (2).
Since bacitracin and neomyein are not closely
related chemically, the possibility had to be
considered that some common contaminants,
and not the antibiotics themselves, were re-
sponsible for the simultaneous allergy. However,
no significant differences between preparations
from various manufacturing firms could be
demonstrated.
Simultaneous hypersensitivity to bacitracin
and neomycin could, of course, be considered as
independent sensitizations to these antibiotics.
In fact, in countries where neomycin prepara-
tions arc seldom combined with bacitracin,
positive reactions to bacitracin have only oc-
casionally been seen in neomycin-sensitive pa-
tients (5, 6). However, the incidence of 80
per cent of simultaneous hypersensitivity to
two different allergens is exceptionally high
(2, 7).
EXPERIMENTAL AND RESULTS
In preliminary investigations, samples of a 10
per cent bacitracin solution were variously treated
resulting in solutions with varying concentrations
of the components, demonstrable by paper electro-
phoresis (3). In the freshly prepared solution, in
addition to the main fraction (I), in all probability
containing bacitracin A, another small fraction
(II) was seen. After four days' incubation at 37° C,
the first fraction had diminished and fraction II
had increased correspondingly. After further incu-
bation the proportion of fraction I had decreased
still further and the presence of new components
could be demonstrated by paper electrophoresis.
The above three solutions were used for quanti-
tative epicutaneous testing of bacitracin-sensitive
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patients. Bacitracin incubated in alkaline solu-
tion, especially after the longer incubation time,
proved to have a clearly weaker eczematogenic
effect than the first, freshly prepared solution. It
thus seemed probable that the eczematogenic
factor is linked with bacitracin A, whereas the
degradation products have little or no eczemato-
genic effect.
A bacitracin solution was incubated for two
days at 37° C (pH 8.6) and fractionated by paper
electrophoresis. The paper strip was split longi-
tudinally, one half being stained for localization of
the various fractions. From the other unstained
half, the sections in which the concentrations of
fractions I and II, respectively, were highest were
used for patch tests. Six bacitracin-sensitive pa-
tients were tested with patches cut from these
areas. The patches containing fraction I gave a
positive reaction in three cases, whereas the tests
with those containing degradation products (II)
gave negative responses. This result again sug-
gests that the eczematogenic agent of bacitracin
is bacitracin A.
Since bacitracin A in aqueous solutions is
readily converted into bacitracin F because of the
greater stability of the latter (8), it was decided
to purify bacitracin F as much as possible and to
compare its eczematogenic effect with that of the
original sample of bacitracin (mainly A).
In order to find a suitable technic for the pro-
duction of relatively large amounts of bacitracin
F, the following investigations were conducted.
In the first series of experiments, the degradation
of bacitracin as a function of time, at 37° C, pH 9
was investigated. A 10 per cent solution of baci-
tracin was prepared in borate buffer (pH 5.6, u =
0.5) and the p11 adjusted to 9 with 2 N sodium
hydroxide. The mixture was incubated at 37° for
50 days. 0.1 ml samples were withdrawn at 1 to 2
day intervals and subjected to paper electrophore-
sis (borate buffer, pH 8.6, u = 0.5, 12 V/cm, 3 hrs,
in a LKB No. 3276 apparatus). The paper strips
were dried after the run and sprayed with nm-
hydrin (0.3 per cent ninhydrin in 94 per cent
ethanol). In order to obtain a rough quantitation
of the fractions, the color intensities of the sepa-
rated bands were measured in a Spinco Model R
Analytrol scanner, using cam No. B3. (Since the
cam is intended for the measurement of another
color, the instrument was calibrated for this
estimation with solutions containing known
amounts of bacitracin.)
Typical examples of the electrophoretic runs
are seen in Fig. 1. The original preparation (a)
contains one major fraction (I) and a minor com-
ponent (II), which moves slightly faster towards
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the anode than band I. Samples b, c and d were
taken after incubation for 5, 9 and 44 days, respec-
tively. The experiment illustrates the gradual
reduction in the amount of fraction I during the
incubation. This is accompanied by a simultaneous
strengthening of band II, followed by the later
emergence of the third, more diffuse band III.
Since the two latter bands partially overlap it
was not possible to make accurate determinations
of the relative amounts of these fractions. While I
and II move as fairly narrow bands, the third
fraction is broader and shallower, suggesting that
this band may consist of several components. The
total amount of ninhydrin-reactive material was
constant throughout the incubation. A barely
detectable minor component which moved rapidly
towards the cathode was present in every electro-
phoretic run. The only antibiotically active frac-
tion was I.
For the purification of large amounts of bad-
tracin F a 10 per cent solution of the bacitracin
preparation in borate buffer was incubated for 7
days at 37°. The above experiments showed that a
high yield of bacitracin F could be obtained with
this treatment.
For the identification of the components,
samples of an incubated solution containing suit-
able amounts of the three fractions were run on
four parallel strips. After electrophoresis, one was
sprayed with ninhydrin and sections correspond-
ing to the dyed bands were cut out of the other
strips and eluted with water. The spectra of the
fractions were taken in a Beckman DR-i spectro-
photometer against appropriate buffer blanks. The
results are seen in Fig. 2. When the absorption
curves are compared with those published in the
literature (8), it seems safe to conclude that the
major components of fractions I and II are baci-
tracin A and F, respectively. The spectrum of
fraction III gives no indication of its composition,
Fm. 1. Electrophoretic separation of components in incubated bacitracin samples. Strip a: no incu-
bation, b: sample incubated at 37°C, pH 9, for 5 days, c: for 9 days, and d: for 44 days.
I
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FIG. 2. Spectra of the electrophoretically
separated fractions I, II, and III. For details see
text.
which was not further investigated. Because the
preliminary investigations had shown that the
eczematogenic effect of bacitracin solutions de-
creases progressively during prolonged incubation,
the isolation of this fraction (III) for testing pur-
poses was omitted.
Since paper electrophoresis is not convenient
for the separation of large amounts of substances,
other supporting media for the separation were in-
vestigated. In preliminary experiments with
starch gel electrophoresis the recovery of the frac-
tions seemed poor. Another medium, Pevikon-C-
870, which appeared to be more convenient for this
purpose and gave reasonably good recoveries, was
chosen as the supporting material for the actual
purifications. Pevikon is a powdered co-polymer of
polyvinylchloride and polyvinylacetate (9). The
substance was washed well with distilled water and
mixed with the electrophoresis buffer. The result-
ing slurry was poured into a plastic (Perspex,
ICI, Great Britain) trough. The size of the vessel
was 20 cm x 40 cm x 1.2 cm. Two milliliters of the
incubated 10 per cent bacitracin solution were
pipetted into a narrow slit made in the Pevikon
bed. 12 V/cm were applied for 20 hours at room
temperature. The fractions, which appeared
yellow against the white background, were easily
located and recovered by transferring the appro-
priate region of the Pevikon bed onto filter paper
and eluting with distilled water. The eluates from
repeated runs were freeze-dried and dissolved in a
small amount of water. Residual grains of Pevikon
were removed by filtration.
The isolated fractions were identified by com-
parative paper electrophoresis, with a known
degraded bacitracin sample as reference, and by
spectrophotometric analysis. Bacitracin F ob-
tained in this way yielded in paper electrophoresis
a single narrow band, which gave the typical
spectrum of bacitracin F. A faint band, which cor-
responded to fraction I (bacitracin A) indicated
that the preparation was slightly contaminated.
The amount of this fraction in our preparations of
bacitracin F was estimated to be about 1 to 3 per
cent. The eczematogenic effect of bacitracin F
purified by preparative electrophoresis ("F") and
of the original commercial bacitracin ("A"),
consisting mainly of bacitracin A, were compared
by means of epicutaneous tests on 11 patients
hypersensitive to bacitracin. For this purpose
aqueous solutions of both these materials were
prepared in dilutions of 3.2%, 1%, 0.32%, etc.
The adhesive chamber method (Rokstad) modified
by Pirilt (1C) was used.
"A" gave positive reactions in all cases, the
threshold varying from 3.2% to 0.01%. In four
cases the lowest concentration causing a reaction
was higher than 0.3%. In all these cases—in a total
of 8 test series—"F" gave negative reactions even
at the 3.2% concentration. On the other seven
patients the threshold of sensitivity to bacitracia
was 0.1% or lower. In one of these cases, in which
the threshold of sensitivity to "A" was 0.1%,
the tests with "F" were performed twice with
negative result. In the other six cases (threshold
to "A" from 0.1 to 0.01%), it was possible to com-
pare the eczematogenic effects of "A" and "F"
quantitatively, positive reactions to both of them
being obtained in all the 12 test series performed.
The ratio of "A" to "F", which varied in indi-
vidual tests from 10:1 to higher than 100:1, was
found to be 32—100:1 oa the average.
aiscussion
It can be concluded that when the antibiotically
active form of bacitracin A is converted to F,
the cczcmatogenic effect probably disappears.
The traces of bacitracin A still present in baci-
tracin F purified by preparative electrophoresis
(see above) explain the positive reactions to this
fraction, the threshold concentrations being
32—100 times higher on average than with the
original bacitracin.
According to Konigsbcrg and Craig (11),
bacitracin F is formed from A by oxidation of
the N-terminal amino group of the isoleucinc
residue to form a ketone and by oxidation of the
thiazoline ring to thiazole. The thiazoline ring
system, which is considered to be responsible
for the antibiotic activity of A (8), may be the
essential structure for the sensitizing effect too,
although the results presented above do not
warrant definite conclusions on this point.
SUMMARY
By preparative electrophoresis of commercial
bacitracin incubated at 37° C in alkaline solu-
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tion, bacitracin F (the primary degradation
product of A) in relatively pure form could be
obtained. Comparative epicutaneous testing on
11 patients hypersensitive to bacitracin demon-
strated that the eezematogenic effect of the
purified F was very weak. The conversion of
bacitracin A to F with disappearance of anti-
biotic activity is accompanied by decisive re-
duction—probably complete loss—of the ec-
zematogenic effect.
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